One HA stalk topping multiple heads as a novel influenza vaccine

References

• Kim Y-H, Hong K-J, Kim H, et al. Influenza vaccines: past, present, and future. Rev Med Virol. 2022;32(1):e2243.
   PubMed Web of Science ®Google Scholar
• Iacobucci G. Covid-19: Risk of death more than doubled in people who also had flu, English data show. Br Med J. 2020;370:m3720.
   PubMedGoogle Scholar
• Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020;92(11):2870–2873.
   PubMed Web of Science ®Google Scholar
• Chiu C. Seasonal influenza vaccines and hurdles to mutual protection. Clin Microbiol Infect. 2016;22(Suppl 5):S113–S119.
   PubMedGoogle Scholar
• Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34(26):2926–2933.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519–1524.
   PubMed Web of Science ®Google Scholar
• Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189–202.
   PubMed Web of Science ®Google Scholar
• Wei C-J, Crank MC, Shiver J, et al. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020;19(4):239–252.
   PubMed Web of Science ®Google Scholar
• Stevens J, Corper AL, Basler CF, et al. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004;303(5665):1866–1870.
   PubMed Web of Science ®Google Scholar
• Janssens Y, Joye J, Waerlop G, et al. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation. Front Immunol. 2022;13:959379.
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Andrews SF, Wheatley AK, et al. Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight. 2019;4(22).
   PubMed Web of Science ®Google Scholar
• Ermler ME, Kirkpatrick E, Sun W, et al. Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model. J Virol. 2017;91(12).
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87(12):6542–6550.
   PubMed Web of Science ®Google Scholar
• Margine I, Krammer F, Hai R, et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 2013 Oct;87(19):10435–10446.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens C, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1.
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2.
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Dharmapuri S, Cirillo A, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine. 2009;27(9):1293–1300.
   PubMed Web of Science ®Google Scholar
• Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190(6):2720–2735.
   PubMed Web of Science ®Google Scholar
• Xu K, An Y, Li Q, et al. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerg Microbes Infect. 2021;10(1):1574–1588.
   PubMed Web of Science ®Google Scholar
• Aartse A, Eggink D, Claireaux M, et al. Influenza A virus hemagglutinin trimer, head and stem proteins identify and quantify different hemagglutinin-specific B cell subsets in humans. Vaccines (Basel). 2021 Jul 2;9(7).
   PubMed Web of Science ®Google Scholar
• McCarthy KR, Lee J, Watanabe A, et al. A prevalent focused human antibody response to the influenza virus hemagglutinin head interface. mBio. 2021 Jun 29;12(3):e0114421.
   PubMed Web of Science ®Google Scholar
• Bangaru S, Lang S, Schotsaert M, et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell. 2019 May 16;177(5):1136–1152 e18.
   PubMed Web of Science ®Google Scholar
• Dong J, Gilchuk I, Li S, et al. Anti-influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface. J Clin Invest. 2020 Sep 1;130(9):4734–4739.
   PubMed Web of Science ®Google Scholar
• Chen C-J, Ermler ME, Tan GS, et al. Influenza A viruses expressing intra- or intergroup chimeric hemagglutinins. J Virol. 2016;90(7):3789–3793.
   PubMed Web of Science ®Google Scholar
• Hai R, Krammer F, Tan GS, et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol. 2012;86(10):5774–5781.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chi Y, Tang X, et al. Rapid, efficient, and modular generation of adenoviral vectors via isothermal assembly. Curr Protoc Mol Biol. 2016;113(1).
   PubMedGoogle Scholar
• Baek M, DiMaio F, Anishchenko I, et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373(6557):871–876.
   PubMed Web of Science ®Google Scholar
• Song Y, DiMaio F, Wang RY-R, et al. High-resolution comparative modeling with RosettaCM. Structure. 2013;21(10):1735–1742.
   PubMed Web of Science ®Google Scholar
• Raman S, Vernon R, Thompson J, et al. Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins. 2009;77(Suppl 9):89–99.
   PubMedGoogle Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
   PubMed Web of Science ®Google Scholar
• de Beer TAP, Berka K, Thornton JM, et al. PDBsum additions. Nucleic Acids Res. 2014;42(Database issue):D292–D296.
   PubMedGoogle Scholar
• Hubbard SJ, Thornton JM, Campbell SF. Substrate recognition by proteinases. Faraday Discuss. 1992;93:13–23.
   Web of Science ®Google Scholar
• Song Y, Wang X, Zhang H, et al. Repeated low-dose influenza virus infection causes severe disease in mice: a model for vaccine evaluation. J Virol. 2015;89(15):7841–7851.
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21(9):1065–1070.
   PubMed Web of Science ®Google Scholar
• Caton AJ, Brownlee GG, Yewdell JW, et al. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31(2 Pt 1):417–427.
   PubMed Web of Science ®Google Scholar
• Xu R, Ekiert DC, Krause JC, et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328(5976):357–360.
   PubMed Web of Science ®Google Scholar
• Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289(5796):373–378.
   PubMed Web of Science ®Google Scholar
• Coudeville L, Bailleux F, Riche B, et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
   PubMed Web of Science ®Google Scholar
• Fox JP, Cooney MK, Hall CE, et al. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982;116(2):228–242.
   PubMed Web of Science ®Google Scholar
• McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother. 2012;8(1):34–44.
   PubMed Web of Science ®Google Scholar
• Ng S, Fang VJ, Ip DKM, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013;208(8):1320–1324.
   PubMed Web of Science ®Google Scholar
• He W, Tan GS, Mullarkey CE, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A. 2016;113(42):11931–11936.
   PubMed Web of Science ®Google Scholar
• Henry Dunand CJ, Leon PE, Huang M, et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe. 2016;19(6):800–813.
   PubMed Web of Science ®Google Scholar
• Kirchenbaum GA, Ross TM. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol. 2014;28:71–76.
   PubMed Web of Science ®Google Scholar
• Tan GS, Leon PE, Albrecht RA, et al. Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog. 2016;12(4):e1005578.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Joyce MG, Gillespie RA, et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019;20(3):362–372.
   PubMed Web of Science ®Google Scholar
• Kang YF, Sun C, Sun J, et al. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat Commun. 2022 May 13;13(1):2674.
   PubMed Web of Science ®Google Scholar
• Sayedahmed EE, Kumari R, Shukla S, et al. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine. 2018;36(45):6744–6751.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237–248.
   PubMed Web of Science ®Google Scholar
• Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654–1664.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Sakurai F, Tachibana M, Mizuguchi H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab Pharmacokinet. 2022;42:100432.
   PubMed Web of Science ®Google Scholar